By Lloyd Mager
Adherence to track and track guidelines helps ensure the safety of the drug supply chain, while delivering business benefits that can add value to pharmaceutical companies, their contract partners, and others involved in the supply chain. Though serialization or identification efforts were initiated in different markets across the globe over the past decade, some organizations are more prepared than others to face the challenges and leverage the opportunities presented by track and trace.
Though the timelines may vary, across the globe more and more countries are requiring product identifiers and serialization of prescription drugs — right down to individual salable units. Some countries have required static coding since the 1990s, while others began requiring variable coding (to include serialization, expiry and lot number) in the 2000s, and the U.S. and Canada have until (insert date here)to comply with guidelines for unique product identification.
As global guidelines take full effect, it is worth understanding how contract manufacturing organizations are preparing themselves to comply to meet the needs of their customers.